Preparatory Lectures   1) Viral Hepatitis Primer   2) End-stage Liver Disease 

7:30 am Registration, Breakfast and View Exhibits

8:00 am Opening Comments and Pre-Test

8:20 am Viral Hepatitis: Updates for 2026

Part 1 – HBV and HCV

·        Viral Hepatitis Elimination - Caring for At-risk populations – homeless, PWID, the incarcerated, HIV-infected individuals

·        Current DAA Therapies and Screening pipelines

Part II – Delta Hepatitis and HEV

·        New antivirals and interferon-based strategies

·        Bulevirtide for HDV 

9:00 am Cholestatic Liver Disease: Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Pruritus                         

·        Disease pathogenesis, progression and systemic drivers

·        Key therapeutic agents – past, present and future

·        Pruritus management, fatigue and watching for complications

9:40 am     Break and View Exhibits

10:05 am Metabolic Liver Disease: MASLD, MASH and Fibrosis

·        Metabolic origins and systemic drivers

·        Treatment evolution: from lifestyle changes to GLP-1’s to breaking therapies

· Case Study: Managing the MASLD patient who has other comorbidities

10:45 am Alcohol Associated Liver Disease                                                                                                           

·        The growing prevalence of alcohol over-consumption and its impact on liver health

·        From steatosis to hepatitis to fibrosis to cirrhosis

· Promising therapeutic agents for AAH and other alcohol associated liver disease

11:30 am Lunch and Clinical Product Theaters

‍ ‍·‍ ‍Dessert and Meet the Exhibitors

12:45 pm Hepatocellular Carcinoma: New Systemic Treatment Options                                                                                        

·        A case-based approach to HCC screening and treatment

·        New data on the benefit of downstaging – TACE, TARE, Ablation

·        Promising 1st and 2nd line therapies for liver cancer

·        New chemotherapy regimens in development and Immunotherapy as the new MoA

· Checkpoint inhibitors and VEGE inhibitors

1:40 pm End-stage Liver Disease and Cirrhosis Management

·        Portal hypertension, decompensation triggers and ascites

·        The signs and treatments for Hepatic Encephalopathy

·        Liver transplant processes and organ availability

2:20 pm Closing Panel: Integrating the Liver Disease Continuum

·        Join the faculty for a lively discussion along the continuum of live disease recognition and treatment approaches

·        Working effectively with clinicians in your area

·        Managing the referral process

·        Post Test and analysis and discussion

2:50 pm Closing Comments, and Wrap-Up                                                                                

Seminar adjourns at 3:00pm

Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome (30 mins)                                                            

Lecture 4 – AASLD Update – Highlights of the 2025 AASLD Liver Meeting (60 mins)

Course Director:  Paul J. Pockros, MD - Scripps Health